HUMAHumacyte, Inc.

Nasdaq humacyte.com


$ 8.78 $ 0.39 (4.64 %)    

Tuesday, 16-Jul-2024 15:59:44 EDT
QQQ $ 496.22 $ 0.19 (0.04 %)
DIA $ 409.69 $ 7.30 (1.81 %)
SPY $ 564.93 $ 3.33 (0.59 %)
TLT $ 94.14 $ 1.31 (1.41 %)
GLD $ 228.28 $ 4.46 (1.99 %)
$ 8.79
$ 8.99
$ 8.77 x 100
$ 9.00 x 100
$ 8.22 - $ 8.99
$ 1.96 - $ 9.97
6,081,684
na
951.48M
$ 1.57
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-24-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-29-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-K
15 11-13-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 whats-going-on-with-huamacyte-shares-tuesday

Humacyte has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement wit...

 btig-maintains-buy-on-humacyte-raises-price-target-to-11

BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and raises the price target from $8 to $11.

 pluristyx-announces-license-agreement-with-humacyte-humacyte-to-use-pluristyxs-clinical-grade-pluribank-ipsc-line-for-manufacturing-insulin-producing-cells-for-biovascular-pancreas-product

Partnership Includes Access to panCELLa™ Platform for Generating Hypoimmune Cells for Clinical Implantation

 cantor-fitzgerald-reiterates-overweight-on-humacyte-maintains-7-price-target

Cantor Fitzgerald analyst Kristen Kluska reiterates Humacyte (NASDAQ:HUMA) with a Overweight and maintains $7 price target.

 benchmark-reiterates-buy-on-humacyte-maintains-15-price-target

Benchmark analyst Bruce Jackson reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $15 price target.

 why-humacyte-stock-is-trading-15-higher-monday

Humacyte received the Food and Drug Administration's Regenerative Medicine Advanced Therapy designation for its Acellular ...

 humacyte-presents-preclinical-data-for-its-biovascular-pancreas-program

– BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes – – Humacyte&#...

 tommy-tuberville-sells-several-large-stock-positions-makes-new-buys-heres-what-the-us-senator-is-betting-on-now

Senator Tommy Tuberville disclosed numerous stock trades on Friday June 14. A look at some of the key highlights.

 centers-for-medicare--medicaid-services-issues-icd-10-pcs-codes-for-humacytes-human-acellular-vessel

– Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using...